Crop Research Uncovers a Cancer-Killing CRISPR

Most CRISPR technologies developed for medicine rely on editing DNA. Cas12a2 is different. Rather than repairing a disease-causing mutation, the bacterial nuclease recognises a specific RNA sequence and, once activated, enters a highly destructive collateral cleavage state that degrades DNA and RNA throughout the cell, ultimately triggering cell death. In bacteria, this serves as an abortive infection mechanism to stop viral spread. In cancer, researchers have repurposed the same mechanism so that tumour-specific mutations act as the trigger for destroying malignant cells.

The enzyme’s route to oncology began in an unexpected place. Confluence Genetics, a US crop genetics company developing improved soybean varieties, originally identified Cas12a2 while screening microbial genomes for novel CRISPR systems that might expand the plant genome engineering toolbox. During those studies, the researchers found that one group of nucleases performed poorly as genome editors because they consistently killed the host bacteria instead. Rather than abandoning the discovery, they investigated the underlying biology, revealing a previously uncharacterised CRISPR defence mechanism that has now become the basis of the company’s Cas-CLEAR oncology platform.

The launch follows two independent Nature papers published this year that validate the concept in human cells. In one study, Jennifer Doudna’s laboratory at the University of California, Berkeley demonstrated that Cas12a2 can selectively eliminate cells carrying cancer-associated mutations, including mutations in the historically undruggable tumour suppressor gene TP53, and showed activity in mouse models of liver and lung cancer. A second study, led by researchers at Utah State University and University of Utah Health, showed that the same nuclease could distinguish cancer cells carrying a single-base KRAS mutation from healthy cells.

Alongside the platform launch, Confluence has released a bioRxiv preprint describing nine newly identified Cas12a2 orthologues isolated from diverse environmental and host-associated microbial communities. Three enzymes – RsCas12a2, SdCas12a2 and HmCas12a2 – displayed collateral DNA damage activity comparable with or exceeding the previously characterised SuCas12a2, while differing in target recognition and mismatch tolerance. The authors suggest these complementary properties could allow individual nucleases to be selected for different applications, ranging from cancer therapeutics to diagnostics and agricultural biotechnology.

Although Cas12a2 itself is not a conventional genome-editing enzyme for plants, the story illustrates the increasingly close relationship between agricultural and biomedical CRISPR research. Plant breeding programmes routinely mine environmental microbes for new CRISPR systems with useful molecular properties, and these discoveries often reveal biological mechanisms that extend well beyond crop improvement. In this case, an enzyme initially investigated as a potential breeding tool has instead become the foundation for a precision oncology platform.

The launch of the Cas-CLEAR platform was disclosed in a compay press release on 9 July 2026. The Confluence preprint was led by Anna L. Singer, Emma E. January and Matthew B. Begemann at Confluence Genetics in St Louis, Missouri, and was posted on bioRxiv on 7 July 2026. The clinical rationale for Cas12a2-based cancer therapy is supported by two independent Nature studies published in 2026, led, respectively, by Jennifer Doudna’s group at the University of California, Berkeley, and by Paul Scholz and colleagues from Utah State University and University of Utah Health. The two latter papers were discussed on CRISPR Medicine News on 10 June 2026.